MedTrace Logo

Concurrent Chemoradiotherapy With Docetaxel and Cisplatin in Esophageal Cancer

NCT01640860 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2012-07-17

No results posted yet for this study

Summary

This study is designed to determined the feasibility and safety in advanced esophageal cancer treated with docetaxel and cisplatin cocurrent chemoradiotherapy. The primary end points were clinical best response and response rate and secondary endpoints were progression free survival and overall survival.

Conditions

  • Esophageal Cancer

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Chonnam National University Hospital

    lead OTHER

Principal Investigators

  • Sang-Hee Cho, MD. PhD · CNUHH

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-12-31
Completion
2011-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01640860 on ClinicalTrials.gov